(4S,6S,1'S)-6-(1-amino-2-phenylethyl)-4-benzyl-2-phenyl-3-aza-2-bora-1-oxacyclohexane | 165315-39-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4S,6S,1'S)-6-(1-amino-2-phenylethyl)-4-benzyl-2-phenyl-3-aza-2-bora-1-oxacyclohexane
• 英文别名: (S)-1-((4S,6S)-4-benzyl-2-phenyl-1,3,2-oxazaborinan-6-yl)-2-phenylethan-1-amine；(1S)-1-[(4S,6S)-4-benzyl-2-phenyl-1,3,2-oxazaborinan-6-yl]-2-phenylethanamine
• CAS: 165315-39-9
• 化学式: C₂₄H₂₇BN₂O
• 分子量: 370.302
• InChiKey: FMDWMAAXLSBSDP-HJOGWXRNSA-N

物化性质

• 沸点：
  508.6±42.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.94
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S,6S,1'S)-6-(1-amino-2-phenylethyl)-4-benzyl-2-phenyl-3-aza-2-bora-1-oxacyclohexane 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 0.25h， 生成 {(1S,2S,4S)-1-Benzyl-4-[(S)-2-((S)-2-benzyloxycarbonylamino-propionylamino)-3-methyl-butyrylamino]-2-hydroxy-5-phenyl-pentyl}-carbamic acid thiazol-5-ylmethyl ester
  参考文献：
  名称：

  Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants

  摘要：

  Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.

  DOI：

  10.1021/ja982893p
• 作为产物：
  描述：

  SSS-2,5-diamino-1,6-diphenyl-3-hexanol 、 苯硼酸 在 苯硼酸 作用下， 生成 (4S,6S,1'S)-6-(1-amino-2-phenylethyl)-4-benzyl-2-phenyl-3-aza-2-bora-1-oxacyclohexane
  参考文献：
  名称：

  Pharmaceutical composition for inhibiting HIV protease

  摘要：

  本发明揭示了一种药物组合物，其包括一种HIV蛋白酶抑制剂化合物的溶液，所述溶液是在一种药学上可接受的有机溶剂中制备的，所述有机溶剂包括以下混合物：（1）（a）从丙二醇和聚乙二醇中选择的溶剂或（b）从聚氧乙烯甘油三蓖麻油酸酯、聚乙二醇40氢化蓖麻油、分馏椰子油、聚氧乙烯（20）山梨醇单油酸酯和2-（2-乙氧基乙氧基）乙醇中选择的溶剂或（c）其混合物和（2）乙醇或丙二醇。

  公开号：

  US05484801A1

文献信息

• Pharmaceutical composition
  申请人：Abbott Laboratories

  公开号：US05559158A1

  公开（公告）日：1996-09-24

  A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.

  揭示了一种固体药物组合物，包括一种药学上可接受的吸附剂或一种药学上可接受的吸附剂混合物，该吸附剂或吸附剂混合物吸附了（1）一种药学上可接受的有机溶剂或一种药学上可接受的有机溶剂混合物，（2）一种HIV蛋白酶抑制化合物和（3）一种或多种药学上可接受的酸。该固体组合物可以选择性地封装在硬明胶胶囊中。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05541206A1

  公开（公告）日：1996-07-30

  A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

  公开了一种具有以下式子的逆转录病毒蛋白酶抑制化合物：##STR1##。
• Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants
  作者：Taekyu Lee、Van-Duc Le、Dongyeol Lim、Ying-Chuan Lin、Garrett M. Morris、Andrew L. Wong、Arthur J. Olson、John H. Elder、Chi-Huey Wong

  DOI：10.1021/ja982893p

  日期：1999.2.1

  Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.
• Pharmaceutical composition for inhibiting HIV protease
  申请人：Abbott Laboratories

  公开号：US05484801A1

  公开（公告）日：1996-01-16

  A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.

  一种药物组合物被披露，其包括一种HIV蛋白酶抑制化合物的溶液，所述溶液在一种药用可接受的有机溶剂中，所述有机溶剂包括以下混合物：(1) (a) 从丙二醇和聚乙二醇中选择的溶剂，或者 (b) 从聚氧乙烯甘油三蓖麻油酸酯、聚乙二醇40氢化蓖麻油、分馏椰子油、聚氧乙烯(20)山梨醇单油酸酯和2-(2-乙氧基乙氧基)乙醇中选择的溶剂，或者 (c) 其混合物，以及 (2) 乙醇或丙二醇。